EIF2A and glaucoma: This strategy has been used to confirm that AAV-Cre mediated eIF2α S51A mutant expression in RGCs results in CHOP inhibition and protects RGC somata and axons in ON crush and glaucoma models.19 Expression of unphosphorylated eIF2α S51A mutant in RGCs significantly increased RGC soma and axon survival in EAE (Figure 5), which confirms that inhibiting the eIF2α-CHOP pathway provides neuroprotection.